A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

NCT05954910 · tracked via the Priya Life Science China tracker

Sponsor

Hoffmann-La Roche

Phase

Observational

Started

2023-08-25

Last updated

2026-07-01

Condition(s) studied

Diffuse Large B-Cell Lymphoma

Investigational drug(s) / intervention(s)

Polatuzumab Vedotin →

Polatuzumab Vedotin: Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.

Study summary

The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Be diagnosed as DLBCL * Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment * Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail * Cohort 3: relapse or refractory to previous treatment Exclusion Criteria: * Participant who currently participates in or with plan to participate in any interventional clinical trial * Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Primary outcome measure(s)

Cohorts 1 and 2: Progression Free Survival at 24 months (PFS24) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma — At 24 months
Cohort 3: PFS Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma — Baseline up to end of study (EOS) (approximately 38 months)

Trial sites (29)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	China	Active Not Recruiting
Peking University Third Hospital	Beijing	China	Recruiting
Beijing Hospital of Ministry of Health	Beijing	China	Active Not Recruiting
Beijing Tongren Hospital, Capital Medical University	Beijing	China	Active Not Recruiting
The First Bethune Hospital of Jilin University	Changchun	China	Active Not Recruiting
Xiangya Hospital of Centre-South University	Changsha	China	Active Not Recruiting
Third Xiangya Hospital of Central South University	Changsha	China	Recruiting
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital	Chengdu	China	Active Not Recruiting
Zhujiang Hospital, Southern Medical University	Guangzhou	China	Active Not Recruiting
Guizhou Cancer Hospital	Guiyang	China	Recruiting
Hainan Cancer Hospital	Haikou	China	Recruiting
Affiliated Hospital of Inner Mongolia Medical University	Hohhot	China	Recruiting
Jiangxi Cancer Hospital	Nanchang	China	Recruiting
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)	Nanjing	China	Active Not Recruiting
Jiangsu Cancer Hospital	Nanjing	China	Active Not Recruiting
The Affiliated Hospital Of Qingdao University	Qingdao	China	Recruiting
Ruijin Hospital Shanghai Jiaotong University School of Medicine	Shanghai	China	Recruiting
Tongji Hospital of Tongji University	Shanghai	China	Active Not Recruiting
China Medical University (CMU) First Affiliated Hospital	Shenyang	China	Recruiting
The Fourth Hospital of Hebei Medical University	Shijiazhuang	China	Active Not Recruiting
Shanxi Province Cancer Hospital	Taiyuan	China	Active Not Recruiting
Tianjin Medical University General Hospital	Tianjin	China	Recruiting
Tianjin Cancer Hospital	Tianjin	China	Recruiting
Xinjiang Medical University Cancer Hospital	Ürümqi	China	Active Not Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan	China	Active Not Recruiting
Wuxi People's Hospital	Wuxi	China	Recruiting
First Affiliated Hospital of Medical College of Xi'an Jiaotong University	Xi'an	China	Active Not Recruiting
The Affiliated Hospital of Xuzhou Medical University	Xuzhou	China	Recruiting
Henan Cancer Hospital	Zhengzhou	China	Recruiting

More Hoffmann-La Roche trials in China

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis Recruiting

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Active, not recruiting

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy Recruiting

Other trials for the same condition

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma Recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Recruiting

Pola-ZR2P in Previously Untreated DLBCL Recruiting

A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05954910 on ClinicalTrials.gov ↗ ← All trials in China